Sotatercept for adults with Eisenmenger syndrome from heart defects
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a drug called sotatercept for people with Eisenmenger syndrome caused by certain unrepaired heart defects. It aims to see if the drug can improve exercise ability and overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific type of unrepaired heart defect (atrial septal defect, ventricular septal defect, or patent ductus arteriosus) that has led to Eisenmenger syndrome.
- Your walking distance in 6 minutes is more than 100 meters.
- You have been on stable doses of your current pulmonary hypertension medications for at least 30 days.
- You have not been hospitalized or had changes to your PAH treatments in the last 30 days.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sotatercept for people with Eisenmenger syndrome or a related heart defect that hasn't been repaired. It may help if current treatments aren't working well enough.
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
Hear when a new Eisenmenger Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.